EGFR and non-small cell lung carcinoma: Ongoing trials are investigating immunotherapy with pemetrexed/platinum +/- bevacizumab on NSCLC patients with EGFR mutations after progression on EGFR-TKIs (the Keynote789 study [ClinicalTrials.gov number, NCT03515837], the CheckMate722 study [ClinicalTrials.gov number, NCT02864251], the TH-138 study [ClinicalTrials.gov number, NCT03786692]).